Antiangiogenic agents for nonmalignant brain tumors. - Wikidata - wikimedia - TriplyDB

Antiangiogenic agents for nonmalignant brain tumors.

Antiangiogenic agents for nonmalignant brain tumors.

http://www.wikidata.org/entity/Q37007819

about

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Pathogenesis of peri-tumoral edema in intracranial meningiomas.Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.Pathogenesis and management of type 2 neurofibromatosis

P2860

Q30364937-1E9EE9FA-E770-46C2-907F-A09E9887A9A3 Q30393183-1BBADA27-6037-42A2-AA81-D8E73F2ADD17 Q35188089-000DA1F3-1628-486F-B458-8A76C6FD08EB Q47424261-0ED2E0CA-C034-4C06-A69B-63057954ACED Q48140644-33B30E66-59E1-4B4F-B2E5-047E6250E468 Q50352841-2EF2F238-D66B-4457-9FAF-F03BDB6887D4 Q51288413-0718E8F8-EFD2-4686-A7DC-11A9E2C6A453 Q52563401-97CF3D8C-4E42-4DFF-9509-6194DF84F2B6 Q57266478-FFAE7670-90C4-462B-A17D-DDCA797E37A2

P2860

Antiangiogenic agents for nonmalignant brain tumors.

http://www.wikidata.org/entity/Q37007819

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiangiogenic agents for nonmalignant brain tumors.

@en

Antiangiogenic agents for nonmalignant brain tumors.

@nl

type

label

Antiangiogenic agents for nonmalignant brain tumors.

@en

Antiangiogenic agents for nonmalignant brain tumors.

@nl

prefLabel

Antiangiogenic agents for nonmalignant brain tumors.

@en

Antiangiogenic agents for nonmalignant brain tumors.

@nl

P1433

Q37007819-574D3A2A-A925-4A4C-9F37-D2687A0F04D0

P1476

Q37007819-8A2C776F-2DD5-4FF2-B374-6CB448E3A93A

P2093

Q37007819-0CEF3EC4-9A5E-409F-9239-F29CA8BA71DF

Q37007819-27098415-C3D0-43F1-8E8B-EC3569BD577C

Q37007819-487FCD37-F4A3-45E8-9A42-42ADF0CEA1A4

Q37007819-8F7DA842-BC7A-4518-A251-1D5096B6C125

Q37007819-95584725-F930-494E-B557-539909BA79E6

Q37007819-9C61A9BE-BD71-4A4D-BE7D-05F734F36ABD

Q37007819-AF19E865-A2A1-4693-B1D0-609612C10368

Q37007819-B2355650-9056-4F0B-B976-1B0588A8D1F1

Q37007819-CF4F0432-B7AD-4BF5-9A92-8F2B6A99DEE0

Q37007819-DB5E1FE5-3A63-4510-944A-EA5C03F504DB

P2860

Q37007819-032CFED4-8927-40D2-B33F-56A4A41603F6

Q37007819-0964848B-164D-408A-88CE-50585D0E6616

Q37007819-1F7563C4-CA1F-42FB-A638-F162CE8D586E

Q37007819-36831D8F-1563-40F6-97CD-B669735FE32E

Q37007819-4FBA8D5D-C132-4C75-B0FA-66C3E2ED3E38

Q37007819-6022E5B9-7449-4FC3-BE90-0FE29D3FA9E2

Q37007819-99F290D6-1198-49AF-9171-C6A6B197C040

Q37007819-A8B68B21-DB2C-4A31-A170-8FC9DC9DB558

Q37007819-AE9E81B1-DCC7-4D80-9D3C-DB9D29779068

Q37007819-C8FF515A-82BC-4BDB-BDFC-054EC4806DC4

P304

Q37007819-EA6F1B74-FFC9-420E-A1E2-A13899E6FE34

P31

Q37007819-87402860-30E9-49AD-A2C0-3640C224AA70

P356

Q37007819-763FD3A1-8AD9-4EE6-B34C-D5801165362A

P433

Q37007819-74709F08-82AA-4F9F-9508-794611B60760

P478

Q37007819-7DABDF82-80A6-425E-803A-C756F7746541

P50

Q37007819-922E1F79-E94B-4CAD-B899-841D4BD027A3

P577

Q37007819-D44325EB-C484-4EE8-BA33-7C8210BC59B7

P698

Q37007819-671705E5-DAA6-400C-AB92-C6D845F45BC1

P932

Q37007819-1628BC6A-999A-419B-968C-FCB27DFB17BE

P356

P1433

Journal of neurological surgery. Part B, Skull base

P1476

Antiangiogenic agents for nonmalignant brain tumors.

@en

P2093

Ammar H Hawasli

http://www.w3.org/2001/XMLSchema#string

David D Tran

http://www.w3.org/2001/XMLSchema#string

David H Gutmann

http://www.w3.org/2001/XMLSchema#string

Douglas R Adkins

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Leonard

http://www.w3.org/2001/XMLSchema#string

John Evans

http://www.w3.org/2001/XMLSchema#string

Joshua B Rubin

http://www.w3.org/2001/XMLSchema#string

Michael R Chicoine

http://www.w3.org/2001/XMLSchema#string

Shahid Waheed

http://www.w3.org/2001/XMLSchema#string

Timothy E Hullar

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.

Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate.

Bevacizumab as a treatment option for radiation-induced cerebral necrosis.

Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review.

Atypical and anaplastic meningiomas treated with bevacizumab.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.

P304

136-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0033-1338262

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Gregory J Zipfel

P577

2013-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24436903

http://www.w3.org/2001/XMLSchema#string

P932

3709924

http://www.w3.org/2001/XMLSchema#string